GlassScriptPhysician profile
Shannon Y Pitts
NPI 1174702849
$3,074.52
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,607 · 2020: $798 · 2024: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $776.38 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $701.21 | 2019-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Allergan, INC. | $290.25 | 2019-2020 | |
| Lundbeck LLC | $212.55 | 2019-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $209.78 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $149.46 | 2019-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $109.97 | 2019-2020 | |
| Alkermes, INC. | $104.08 | 2019-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.21 | 2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $92.34 | 2019-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $57.28 | 2019-2020 | |
| Shire North American Group INC | $52.61 | 2019 | |
| Abbvie INC. | $42.88 | 2024 | |
| Ironshore Pharmaceuticals INC. | $41.31 | 2024 | |
| Supernus Pharmaceuticals, INC. | $38.37 | 2024 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $36.56 | 2019 | |
| Noven Therapeutics, LLC | $18.59 | 2024 | Xelstrym, Secuado |
| Tris Pharma INC | $16.22 | 2019 | |
| Bausch Health US, LLC | $14.55 | 2020 | |
| Acadia Pharmaceuticals INC | $13.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Pitts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.